Clinical Trial Update: Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema [Phase 2]

View source ↗

Summary

Phase 2 study evaluating SAR447537 (INBRX-101) vs plasma-derived A1PI therapy in adults with Alpha 1-Antitrypsin Deficiency–related emphysema has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alpha-1 Antitrypsin Deficiency
• Emphysema

Drugs mentioned

• SAR447537 (INBRX-101) (SAR447537)

Snippet

Sponsor: Sanofi | Conditions: Alpha 1-Antitrypsin Deficiency, Emphysema | Phase 2 | Status: COMPLETED